Physician profile
Mark E Miller
NPI 1184676041
$3,458.10
in general payments reported to CMS, 2019-2025
39 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.32 · 2020: $538 · 2021: $317 · 2022: $631 · 2023: $1,094 · 2024: $608 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $484.96 | 2023-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $273.75 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $244.97 | 2022-2023 | Austedo Xr, Austedo |
| Abbvie INC. | $236.43 | 2021-2024 | |
| Novo Nordisk INC | $223.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $204.85 | 2020-2024 | Xarelto |
| Pfizer INC. | $174.59 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.18 | 2022-2024 | Trulance, Xifaxan |
| Hologic Sales and Service, LLC | $127.78 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $111.02 | 2020-2024 | Farxiga, Evusheld, Airsupra |
| Astellas Pharma US INC | $87.64 | 2020-2024 | Veozah, Myrbetriq |
| Indivior INC. | $81.94 | 2023-2024 | Perseris, Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.92 | 2020-2024 | Jardiance |
| Abbott Laboratories | $75.05 | 2019-2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $73.94 | 2020-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.58 | 2020-2022 | |
| Exact Sciences Corporation | $69.22 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $65.84 | 2023-2024 | |
| Kyowa Kirin, INC. | $65.33 | 2022 | |
| Glaxosmithkline, LLC. | $63.76 | 2020-2022 | |
| Radius Health, INC. | $52.13 | 2021-2025 | Tymlos |
| Neurocrine Biosciences, INC. | $48.02 | 2020-2023 | Ingrezza |
| Lundbeck LLC | $47.78 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $44.62 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $38.89 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Alfasigma USA, INC. | $31.38 | 2021-2022 | |
| Kerecis Limited | $31.17 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Mylan Specialty L.P. | $30.20 | 2024 | Yupelri |
| Sumitomo Pharma America, INC. | $27.83 | 2023-2024 | Gemtesa |
| Axsome Therapeutics, INC. | $22.40 | 2023 | Auvelity |
| Verona Pharma, INC. | $18.23 | 2025 | Ohtuvayre |
| Eisai INC. | $17.34 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.07 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.74 | 2020 | |
| Amgen INC. | $15.07 | 2024 | Otezla, Repatha |
| Avanir Pharmaceuticals, INC. | $15.00 | 2021 | |
| Antares Pharma, INC. | $14.82 | 2025 | Xyosted |
| Allergan, INC. | $14.67 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.